Monopar Therapeutics
About Monopar Therapeutics
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$13.7M
- Total assets
- $140.7M
- Market cap
- $398.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $16.7M
- Operating income
- -$16.7M
- Income tax
- $800
- Net income
- -$13.7M
- EPS (basic)
- $-1.85
Balance sheet
- Total assets
- $140.7M
- Current assets
- $140.5M
- Total liabilities
- $2.9M
- Current liabilities
- $2.7M
- Shareholders’ equity
- $137.8M
Cash flow
- Operating cash flow
- -$12.2M
- Investing cash flow
- -$63.5M
- Financing cash flow
- $91.6M
- Net cash flow
- $15.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $398.5M
- Shares outstanding
- 6.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 19, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $13.7M in FY2025.
- Trading 41% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Monopar Therapeutics.
Write a review
News about Monopar Therapeutics
News & sentiment via Polygon.io
